COVID-19 mRNA vaccines preserve immunogenicity after re-freezing

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Grau Cerrato, Santiago
• dc.contributor.author Martín García, Elena, 1975-
• dc.contributor.author Ferrández, Olivia
• dc.contributor.author Martín, Raquel
• dc.contributor.author Tejedor Vaquero, Sonia, 1988-
• dc.contributor.author Gimeno, Ramón
• dc.contributor.author Magri, Giuliana, 1978-
• dc.contributor.author Maldonado, Rafael, 1961-
• dc.date.accessioned 2022-06-16T06:07:07Z
• dc.date.available 2022-06-16T06:07:07Z
• dc.date.issued 2022
• dc.description.abstract The massive COVID-19 vaccine purchases made by high-income countries have resulted in important sample losses, mainly due to the complexity of their handling. Here, we evaluated the possibility of preserving the immunogenicity of COVID-19 mRNA vaccines after re-freezing vials, following the extraction of the maximum possible number of samples, as an alternative approach to minimizing their wastage. Thus, we exposed the vaccine vials to different re-freezing conditions and evaluated mRNA integrity and the effects in mice after in vivo administration. We reveal that the mRNA integrity of Comirnaty® and Spikevax® vaccines remained unaffected after re-freezing during 1 month at -20 °C or -80 °C. The immunological responses also remained unchanged in mice after these re-freezing conditions and no apparent side effects were revealed. The preservation of mRNA integrity and immunogenicity under these handling conditions opens the possibility of re-freezing the mRNA COVID-19 vaccine vials to limit their wastage and to facilitate vaccination processes.
• dc.format.mimetype application/pdf
• dc.identifier.citation Grau S, Martín-García E, Ferrández O, Martín R, Tejedor-Vaquero S, Gimeno R, Magri G, Maldonado R. COVID-19 mRNA vaccines preserve immunogenicity after re-freezing. Vaccines (Basel). 2022 Apr 12;10(4):594. DOI: 10.3390/vaccines10040594
• dc.identifier.doi http://dx.doi.org/10.3390/vaccines10040594
• dc.identifier.issn 2076-393X
• dc.identifier.uri http://hdl.handle.net/10230/53505
• dc.language.iso eng
• dc.publisher MDPI
• dc.relation.ispartof Vaccines (Basel). 2022 Apr 12;10(4):594
• dc.rights © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri https://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword COVID-19
• dc.subject.keyword SARS-CoV2
• dc.subject.keyword mRNA
• dc.subject.keyword Vaccination
• dc.subject.keyword Vaccine preservation
• dc.subject.keyword Vaccine wastage
• dc.title COVID-19 mRNA vaccines preserve immunogenicity after re-freezing
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion